Abstract 310P
Background
Detection of genomic biomarkers in ctDNA may guide treatment decisions for patients with advanced stage GI tract cancers. We summarized the frequency of common and clinically relevant alterations from East Asian patients with common GI cancers whose blood was tested by a commercially available comprehensive next generation sequencing (NGS) assay (Guardant360).
Methods
Anonymized test results from Japan, Korea, Taiwan, Hong Kong, and Southeast Asia were reviewed (cut-off June 2020). We identified cases with a diagnosis of colorectal adenocarcinoma (CRC), pancreatic adenocarcinoma (PC), gastric and gastroesophageal adenocarcinoma (GEC), and biliary tract carcinoma (BTC). Samples from patients enrolled in prospective clinical trials were not included. Synonymous mutations and variants of unknown significance were excluded.
Results
Among 191 plasma samples from CRC patients, ctDNA was detected in 174 (91%). Alterations included TP53 (79%), APC (61%), KRAS (47%), PIK3CA (18%), FGFR1 amp (11%), NRAS (6%), BRAF V600E (6%), ERBB2 amp (5%), MET amp (5%), FGFR2 amp (4%). In 236 samples from PC patients (204 with ctDNA, 86%), alterations included: TP53 (70%), KRAS (69%), PIK3CA (4%), BRCA2 (3%), FGFR1 amp (3%), BRCA1 (1%). In 74 samples from GEC cases (63 with ctDNA, 85%), alterations included: TP53 (59%), ERBB2 amp (16%), KRAS (11%), PIK3CA (6%), FGFR2 amp (6%), MET amp (5%), FGFR1 amp (3%). In 97 samples from BTC patients (84 with ctDNA, 87%), alterations included: TP53 (60%), KRAS (17%), PIK3CA (13%), IDH1 (10%), ERBB2 (4%), FGFR1 amp (4%), IDH2 (1%), BRCA2 (1%), FGFR2 amp or fusion (1% each).
Conclusions
NGS of ctDNA from clinical samples identified common and clinically relevant genomic alterations in East Asian patients with advanced GI cancers. The type and frequency of alterations for each tumor type were similar to those previously reported from tumor tissue banks, although there may be enrichment for resistance mutations due to prior treatment. Given the ease of blood collection over repeat tissue biopsy, these data support consideration of ctDNA NGS for guiding treatment decisions in patients with advanced GI cancers.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Guardant Health AMEA, Inc.
Funding
Guardant Health AMEA, Inc.
Disclosure
M. Muto: Research grant/Funding (institution): Chugai Pharma; Research grant/Funding (institution): Taiho Pharmaceutical; Research grant/Funding (institution): Mitsui Knowledge Industry; Research grant/Funding (institution): Sysmex; Research grant/Funding (institution): Riken Genesis; Research grant/Funding (institution): KBBM Kyoto Bridge for Breakthrough Medicine. M. Lee: Full/Part-time employment: Guardant Health AMEA, Inc. S. Olsen: Shareholder/Stockholder/Stock options: AstraZeneca; Shareholder/Stockholder/Stock options: Guardant Health, Inc.; Full/Part-time employment: Guardant Health AMEA, Inc. All other authors have declared no conflicts of interest.
Resources from the same session
183P - Textbook outcome as a measure of surgical quality assessment and prognosis in gastric neuroendocrine carcinoma: A large multicenter sample analysis
Presenter: You-Xin Gao
Session: e-Poster Display Session
184P - Development and external validation of a nomogram to predict recurrence-free survival after R0 resection for stage II/III gastric adenocarcinoma: An international multicenter study
Presenter: Bin-Bin Xu
Session: e-Poster Display Session
185P - Effect of sarcopenia on short- and long-term outcomes of patients with gastric neuroendocrine tumour after radical surgery: Results from a large, two-institutional series
Presenter: Ling-Qian Wang
Session: e-Poster Display Session
186P - Characterization of the gastroenteropancreatic neuroendocrine tumour patient journey
Presenter: George Fisher Jr
Session: e-Poster Display Session
187P - More is not always better: A multicenter study in lymphadenectomy during gastrectomy for gastric neuroendocrine carcinoma
Presenter: Qi-Yue Chen
Session: e-Poster Display Session
188P - The impact of sarcopenia on chemotherapy toxicity and survival rate among pancreatic cancer patients who underwent chemotherapy: A systematic review and meta-analysis
Presenter: Billy Susanto
Session: e-Poster Display Session
189P - Prognostic value of inflammation-based score for patients treated with FOLFIRINOX (FFX) or gemcitabine plus nab-paclitaxel (GnP)
Presenter: Takahiro Yamamura
Session: e-Poster Display Session
190P - Outcomes from the Asian region of the phase III APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) alone for patients (pts) with resected pancreatic cancer (PC)
Presenter: Joon Oh Park
Session: e-Poster Display Session
191P - First-line liposomal irinotecan + 5 fluorouracil/leucovorin + oxaliplatin in patients with pancreatic ductal adenocarcinoma: Results from a phase I/II study
Presenter: Andrew Dean
Session: e-Poster Display Session
192P - A multicenter crossover analysis of first and second-line FOLFIRINOX or gemcitabine plus nab-paclitaxel administered to pancreatic cancer patients: Results from the NAPOLEON study
Presenter: Kenta Nio
Session: e-Poster Display Session